Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale

Objective: Whether reducing low density lipoprotein cholesterol (LDL-C) is associated with cardiovascular benefits in low risk normocholesterolaemic subjects is unknown. The INTENSITY LOW [Investigating the lowest threshold of vascular benefits from LDL-cholesterol lowering with a PCSK9 mAb inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Kostapanos, Michael S., Cacciottolo, Paul J., Hubsch, Annette, Pavey, Holly, Hurlock, James, Maki-Petaja, Kaisa, Wilkinson, Ian B., Cheriyan, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818119/
https://www.ncbi.nlm.nih.gov/pubmed/31692938
http://dx.doi.org/10.1080/21556660.2019.1677673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818119/
https://www.ncbi.nlm.nih.gov/pubmed/31692938
http://dx.doi.org/10.1080/21556660.2019.1677673

Ejemplares similares